Business
miRagen Announces Leadership Transition and Review of Strategic Alternatives
Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"Lee Rauch appointed President and CEO, following resignation by William Marshall\n miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER, Colo., Sept. 14, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that its Board of Directors has appointed Lee Rauch, the Company’s current Chief Operating Officer, as President, Chief Executive Officer and a Director, following the resignation of William Marshall, Ph.D. Dr. Marshall has also resigned from the Company’s Board of Directors and has agreed to act as Senior Technical Advisor to the Company. “The Board is excited to have Lee take on the CEO role at miRagen at this important time in the Company’s development. We believe that her extensive experience in company building, corporate strategy and business development are invaluable in setting a course for the future of the Company’s activities as we look to build long-term stockholder value,” stated Jeff Hatfield, Chairman of the Board of Directors. “The Board thanks Bill for his years of leadership and tremendous scientific contributions to the advancement of the Company’s microRNA technologies. We wish him well in his future endeavors.” “The miRagen team has built an outstanding RNA therapy discovery platform that has successfully created several clinical and preclinical programs. I’ve been excited to work with this team since joining the Company earlier this year, and I appreciate the Board’s confidence in me to lead the Company as we embark on this next stage of the Company’s development,” stated Ms. Rauch. “In addition, I believe the miRagen team has important capabilities that we can leverage in potential collaborations and other corporate developments.” Ms. Rauch, who joined miRagen in June 2020 as its Chief Operating Officer, has more than 25 years of experience in the biotech and pharmaceutical industries. She has helped build successful companies that range in size from biotech start-ups to multinational pharmaceutical corporations. In her career, Ms. Rauch has held various executive positions at Global Blood Therapeutics (GBT), Onyx Pharmaceuticals, Nuon Therapeutics and COR Therapeutics (acquired by Millennium). Strategi...